MyFinsight
Home
Blog
About
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$66,460K
Free Cash flow
$1,518K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Redemption of term deposits
Decrease in r&d benefit receivab...
Decrease in trade and other paya...
Others
Negative Cash Flow Breakdown
Net loss
(increase)/decrease in other cur...
Other income, net
Decrease in operating lease liab...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-12,268
-14,957
-11,770
-20,958
Depreciation expense
73
72
77
81
Amortization expense
35
34
36
75
Share-based compensation expense
1,308
2,447
-86
2,535
Net foreign exchange impacts
-178
25
-230
918
Other income, net
584
519
880
770
Income tax expense
1
-
0
1
Decrease in trade receivables
0
0
-30
-62
(increase)/decrease in other current assets
2,329
-931
1,741
-5,331
Decrease in r&d benefit receivable
-12,924
209
-190
2,492
Decrease in other long-term assets
0
0
-257
-3,387
Decrease in trade and other payables
2,204
-2,949
-3,576
2,883
Decrease in contract liabilities
0
-404
-32
-88
Decrease in operating lease liabilities
-24
-24
-22
-20
Net cash used in operations
1,518
-15,603
-17,287
-10,891
Redemption of term deposits
64,940
74,427
20,440
71,478
Purchase of term deposits
0
64,427
73,778
20,186
Purchase of property, plant and equipment
0
0
0
3
Net cash provided by/(used in) investing activities
64,940
10,000
-53,338
51,289
Proceeds from issue of ordinary shares
2
0
0
0
Net cash provided by financing activities
2
0
0
0
Increase/(decrease) in cash and cash equivalents
66,460
-5,603
-70,625
40,398
Cash and cash equivalents at start of period
5,657
11,277
82,031
121,330
Effect of exchange rate fluctuations on cash and cash equivalents held
-63
-17
-129
324
Cash and cash equivalents, end of period
72,054
5,657
11,277
82,031
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Redemption of term deposits
$64,940K
(144.52%↑ Y/Y)
Decrease in r&d benefit
receivable
-$12,924K
(-103.75%↓ Y/Y)
Proceeds from issue of
ordinary shares
$2K
(-86.67%↓ Y/Y)
Decrease in trade and
other payables
$2,204K
(165.11%↑ Y/Y)
Share-based compensation
expense
$1,308K
(-76.75%↓ Y/Y)
Net foreign
exchange impacts
-$178K
(98.48%↑ Y/Y)
Depreciation expense
$73K
(-52.60%↓ Y/Y)
Amortization expense
$35K
(-73.48%↓ Y/Y)
Income tax expense
$1K
(-90.00%↓ Y/Y)
Net cash provided
by/(used in) investing...
$64,940K
(241.35%↑ Y/Y)
Net cash used in
operations
$1,518K
(104.45%↑ Y/Y)
Net cash provided by
financing activities
$2K
(-86.67%↓ Y/Y)
Canceled cashflow
$15,205K
Increase/(decrease) in cash and cash
equivalents
$66,460K
(183.05%↑ Y/Y)
Net loss
-$12,268K
(78.05%↑ Y/Y)
(increase)/decrease in other current
assets
$2,329K
(196.00%↑ Y/Y)
Other income, net
$584K
(-68.09%↓ Y/Y)
Decrease in operating
lease liabilities
-$24K
(80.95%↑ Y/Y)
Buy us a coffee